ASCO26: Solid Tumour Data Readouts Outline Merck & Co’s Oncology Prowess

Why It Matters

The data give Merck a near‑term growth runway beyond Keytruda and signal potential new standards of care in head‑and‑neck, endometrial and liver cancers, reshaping competitive dynamics and payer considerations.

Key Takeaways

• Keytruda + radiotherapy yields 84% 2‑yr PFS in HPV+ HNSCC
• Sac‑TMT ADC meets OS and PFS endpoints in advanced endometrial cancer
• EMERALD‑3 shows TACE + STRIDE improves median PFS to 13 months
• Quadruple regimen adds lenvatinib but raises severe adverse events above 60%
• Merck positions sac‑TMT as post‑Keytruda growth asset before Trodelvy readout

Pulse Analysis

Merck’s dual announcements at ASCO 2026 underscore a strategic pivot toward diversified immuno‑oncology assets as Keytruda’s patent cliff looms. The KEYCHAIN trial not only validates pembrolizumab’s synergy with radiotherapy in a non‑surgical, HPV‑positive head‑and‑neck cohort but also offers a compelling safety profile, with grade ≥ 3 events dropping from 46% to 36% versus cisplatin. This could expand Merck’s market share in locally advanced HNSCC, a segment where prior checkpoint‑plus‑chemoradiotherapy attempts have faltered, and set the stage for a pivotal Phase III confirmatory study.

In parallel, the TroFuse‑005 readout positions sacituzumab tirumotecan as the first TROP2‑directed ADC to demonstrate overall‑survival benefit in the post‑platinum, post‑PD‑1 setting for endometrial cancer. By outpacing Gilead’s Trodelvy timeline, Merck may capture a sizable share of the projected $2.2 billion global market by 2030, especially given the drug’s broader biomarker‑agnostic applicability. The positive data also bolsters Merck’s broader ADC platform, reinforcing its ambition to build a post‑Keytruda growth engine across multiple solid‑tumour indications.

AstraZeneca and Eisai’s EMERALD‑3 results add nuance to the evolving HCC treatment landscape. While the STRIDE‑plus‑lenvatinib arm achieved the longest median progression‑free survival, its higher severe‑adverse‑event rate (64%) raises questions about cost‑effectiveness and patient tolerability. Nonetheless, the STRIDE‑only combination delivered a meaningful overall‑survival gain with a more manageable safety profile, suggesting a potential new standard for intermediate‑stage HCC where systemic options remain limited. Regulators will likely demand mature OS data, but the trial’s outcomes could accelerate global submissions and expand access to immunotherapy‑based regimens beyond China, influencing future pricing and reimbursement frameworks.